Howdy, Stranger!

It looks like you're new here. If you want to get involved, click one of these buttons!

In this Discussion

Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.

    Support MFO

  • Donate through PayPal

Biotech Has More Room To Run

FYI: Biotechnology has been one of the best performing industries in the stock market over the past several years. According to S&P Capital IQ, there were numerous catalysts, for this substantial stock outperformance, including several blockbuster drug approvals that drove significant sales and earnings growth. Yet, S&P CIQ thinks the industry’s drivers, including a robust pipeline, remain intact and have a positive fundamental outlook - See more at: http://www.indexologyblog.com/2015/04/17/biotech-has-more-room-to-run/#sthash.O8OC1ZJJ.dpuf
Regards,
Ted
http://www.indexologyblog.com/2015/04/17/biotech-has-more-room-to-run/

ETF Trend Article:
http://www.etftrends.com/2015/04/biotech-etf-run-not-over-yet-says-analyst/

Comments

  • Having a good day so far. GILD, AMGN, CELG and others moving higher.
  • Most of the world is aging demographically and while that has to be priced in to some degree, I think the benefit of developing new drugs and devices is pretty big. It may not be tomorrow, but China is aging quickly too. They spend a tiny amount per capita on healthcare compared to most of the world. Just imagine the opportunity if that many people start spending more on healthcare at a point in life when the need for healthcare generally increases anyway. I'm quite happy to keep buying the dips!
  • edited April 2015
    AMGN with a monster quarter - beat by 38c, beats on rev, raising guidance.
Sign In or Register to comment.